All In Biotech

Drug Trial Radar · NCT07564596

A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

A Phase 1b/2a Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Budoprutug (TNT119) in Adult Subjects With Systemic Lupus Erythematosus (SLE)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Climb Bio, Inc.Industry
Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b/2a, open-label study will evaluate budoprutug in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE, where pharmacodynamics will be evaluated as the change in the number of B cells and immunoglobulins (antibodies) in the blood over time. Budoprutug will be administered as two (2) IV infusions 14 days apart in ascending dose cohorts.

Conditions

  • Systemic Lupus Erthematosus

Interventions

  • BudoprutugDrug

    Single IV dose of study product on Day 1 and Day 15

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to week 28
  2. Incidence of Clinical Laboratory AbnormalitiesTime frame: Up to week 28
  3. Incidence of dose-limiting toxicities (DLTs)Time frame: up to 28 weeks
  4. Change from Baseline in Systolic Blood PressureTime frame: Up to week 28
  5. Change from Baseline in Diastolic Blood PressureTime frame: up to 28 weeks
  6. Change from Baseline in Heart RateTime frame: up to 28 weeks
  7. Change from Baseline in Respiratory RateTime frame: up to 28 weeks
  8. Change from Baseline in Body TemperatureTime frame: up to 28 weeks
  9. Change from Baseline in PR IntervalTime frame: up to 28 weeks
  10. Change from Baseline in QRS DurationTime frame: up to 28 weeks
  11. Change from Baseline in QT IntervalTime frame: up to 28 weeks
  12. Change from Baseline in QTc IntervalTime frame: up to 28 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Baoji Central Hospital

    Baoji, China · Recruiting

  • Peking University People's Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China · Not yet recruiting

  • Xiangya Second Hospital of Central South University

    Changsha, China · Not yet recruiting

  • The First Affiliated Hospital of the University of Science

    Hefei, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang

    Nanchang, China · Not yet recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, China · Not yet recruiting

  • Shanxi Bethune Hospital

    Taiyuan, China · Recruiting

  • Zaozhuang Municipal Hospital

    Zaozhuang, China · Not yet recruiting

  • Mianyang Central Hospital

    Mianyang, Sichuan, China · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.